Unlock Market Insights: Expert Forecasts Driving Stock Performance
Analyst Revisions for Key Market Players
Financial experts on Wall Street have recently updated their assessments for several major companies. Investors can find a detailed overview of all modified analyst ratings, including both upgrades and downgrades, on the dedicated analyst ratings platform.
Freeport-McMoRan Inc. Experiences Target Price Reduction
Scotiabank has lowered its price target for Freeport-McMoRan Inc. (NYSE: FCX) from $55 to $45. Analyst Orest Wowkodaw also downgraded the stock's rating from Sector Outperform to Sector Perform. Freeport-McMoRan's shares concluded trading at $45.36 on Wednesday, and further analyst perspectives on this stock are available for review.
CrowdStrike Holdings, Inc. Sees Increased Price Outlook
Scotiabank has elevated its price target for CrowdStrike Holdings, Inc. (NASDAQ: CRWD) from $440 to $600. Analyst Patrick Colville concurrently upgraded the stock's status from Sector Perform to Sector Outperform. CrowdStrike shares closed at $476.33 on Wednesday, with additional analyst viewpoints accessible.
Alphabet Inc. Benefits from Upgraded Price Target
MoffettNathanson has increased the price target for Alphabet Inc. (NASDAQ: GOOGL) from $230 to $295. MoffettNathanson analyst Michael Nathanson maintained a Buy rating on the stock. Alphabet's shares finished Wednesday's trading at $247.14, and further analyst opinions are available.
CME Group Inc. Receives Positive Rating Shift
Citigroup has raised its price target for CME Group Inc. (NASDAQ: CME) from $275 to $300. Citigroup analyst Christopher Allen upgraded the stock from a Neutral to a Buy rating. CME shares ended Wednesday at $264.43; more analyst insights can be found.
Ameresco, Inc. Achieves Significant Price Target Increase
Jefferies has substantially increased its price target for Ameresco, Inc. (NYSE: AMRC) from $19 to $39. Jefferies analyst Julien Dumoulin-Smith upgraded the stock from a Hold to a Buy rating. Ameresco's shares closed at $31.61 on Wednesday, with further analyst views accessible.
Vertex Pharmaceuticals Incorporated's Target Adjusted Upward
Leerink Partners revised its price target for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from $458 to $456. Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform. Vertex Pharmaceuticals shares settled at $376.62 on Wednesday; additional analyst perspectives are available.
United Natural Foods, Inc. Gains Higher Price Expectation
BMO Capital has increased its price target for United Natural Foods, Inc. (NYSE: UNFI) from $25 to $36. BMO Capital analyst Kelly Bania upgraded the stock from Market Perform to Outperform. United Natural Foods' shares closed at $29.16 on Wednesday, with more analyst opinions readily available.
PepGen Inc. Sees Improved Price Target from HC Wainwright & Co.
HC Wainwright & Co. raised its price target for PepGen Inc. (NASDAQ: PEPG) from $8 to $12. HC Wainwright & Co. analyst Ananda Ghosh maintained a Buy rating on the stock. PepGen shares concluded trading at $2.66 on Wednesday; additional analyst insights can be accessed.
uniQure N.V. Receives Substantial Price Target Boost
Chardan Capital has significantly increased its price target for uniQure N.V. (NASDAQ: QURE) from $35 to $76. Chardan Capital analyst Daniil Gataulin maintained a Buy rating. uniQure shares settled at $47.50 on Wednesday, and further analyst viewpoints are available.
Monopar Therapeutics Inc. Gets Elevated Price Target
BTIG has raised its price target for Monopar Therapeutics Inc. (NASDAQ: MNPR) from $87 to $104. BTIG analyst Jeet Mukherjee maintained a Buy rating on the stock. Monopar Therapeutics shares closed at $73.04 on Wednesday, with more analyst insights provide